Zacks Investment Research
16 Jul 2026, 15:45 UTC · 1h ago
Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
16 Jul 2026, 15:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Pfizer faces a significant patent cliff from 2026 to 2030, with key products including Eliquis and Ibrance losing exclusivity. — Loss of exclusivity on core products creates a structural revenue gap that is difficult to offset and threatens long-term valuation.
-0.80Pfizer's COVID-related revenues are projected to decline further to approximately $5 billion in 2026 from $6.7 billion in 2025. — The consistent downward trajectory of pandemic-era windfalls puts pressure on the company to prove organic growth in other areas.
-0.60The loss of exclusivity cliff is expected to specifically reduce sales by approximately $1.5 billion in 2026. — Provides a concrete, negative quantitative impact on the 2026 top line.
-0.50Continue reading
6 related stories
Top 3 movers · tap to explore
Pfizer's stock has been trading below both its 50-day and 200-day simple moving averages since mid-June. — Technical indicators suggest a lack of buyer conviction and a prevailing bearish trend in the short and medium term.
-0.30Which stocks this story touches
The company is facing declining COVID-related revenues, trading below key moving averages, and a significant upcoming patent cliff.
[mutual] Listed together as pharmaceutical companies in a comparative context.
[mutual] Listed together as pharmaceutical companies in a comparative context.
[mutual] Listed together as pharmaceutical companies in a comparative context.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
21m ago
